-10.5%
ZTS vs MRNA
+516.4%
-526.9%
-69.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.3% | -3.4% | +3.0% | -0.2% |
| 7D | -3.8% | -10.1% | +6.3% | -3.3% |
| 30D | -2.0% | +126.7% | -128.8% | -9.0% |
| 3M | -10.2% | +184.1% | -194.3% | -18.2% |
| 6M | -39.4% | +143.3% | -182.7% | -44.3% |
| YTD | -40.8% | +359.9% | -400.7% | -48.2% |
| 1Y | -50.1% | +454.2% | -504.3% | -57.0% |
| 3Y | -58.9% | +26.0% | -84.9% | -62.0% |
| 5Y | -62.4% | -70.3% | +7.9% | -64.0% |
| All | -10.5% | +516.4% | -526.9% | -25.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling